The Foundayo pill is clinically effective for weight loss. It demonstrated average weight loss of approximately 11 to 12% of body weight over 72 weeks in the ATTAIN phase 3 clinical trial programme and received MHRA authorisation in the UK on 10 August 2026, following a rigorous assessment of both its efficacy and safety profile. A weight loss of 11 to 12% of body weight is clinically meaningful for most patients. It is associated with significant improvements in cardiometabolic risk factors including blood pressure, cholesterol, HbA1c, and inflammatory markers, and is considerably greater than anything achievable with non-GLP-1 weight loss medications currently available in the UK.. In direct clinical context, the Foundayo pill produces somewhat lower average weight loss than injectable Wegovy (semaglutide, approximately 15%) and meaningfully lower than Mounjaro (tirzepatide, approximately 20 to 22%), based on their respective separate clinical trials with different populations. A treatment that can be taken at any time or day without food or water restrictions is one that fits into real life considerably more easily than the alternatives, and for many patients this practical simplicity may make Foundayo the most sustainably adhered-to weight loss option currently available in the UK. The clinical team at J E Williamson Pharmacy in Bishops Stortford is actively tracking the rollout of Foundayo and is ready to help every patient assess whether it is the most effective and appropriate weight loss treatment for their individual health profile, lifestyle, and goals.
Now that Foundayo has received MHRA authorisation, the clinical team at J E Williamson Pharmacy in Bishops Stortford is ready to help you determine whether it or one of the other licensed weight loss treatments currently available represents the strongest, most appropriate fit for your individual health profile and goals. Book now and take advantage of the thorough, personalised clinical assessment that ensures your treatment choice is right for you from the very start.
Key takeaways
- The Foundayo pill produced average weight loss of approximately 11 to 12% of body weight over 72 weeks in ATTAIN-1, the largest ATTAIN trial arm, in adults with obesity without type 2 diabetes
- This level of weight loss is clinically meaningful and is associated with significant improvements in blood pressure, cholesterol, blood sugar, and other cardiometabolic risk factors in the trial populations.
- Foundayo’s efficacy is lower than injectable Wegovy at approximately 15% and Mounjaro at approximately 20 to 22%, based on their respective separate clinical trials rather than direct head-to-head comparison.
- Foundayo’s unique advantage is its flexible oral administration with no food or water restrictions, which may support better long-term adherence for patients who cannot or prefer not to inject.
- In the ACHIEVE-3 head-to-head trial, Foundayo produced greater HbA1c reductions and slightly higher weight loss than oral semaglutide in adults with type 2 diabetes, though with somewhat higher gastrointestinal side effect rates.
- Foundayo is now MHRA-authorised in the UK and should be accessed only through appropriately regulated UK prescribing and pharmacy services following a thorough clinical assessment.
Foundayo in Clinical Trials
The most important source of evidence for Foundayo’s effectiveness is the ATTAIN phase 3 clinical trial programme, a comprehensive set of randomised controlled trials that formed the basis of both the FDA and MHRA regulatory approvals. ATTAIN-1, the largest arm of the programme, enrolled adults with obesity but without type 2 diabetes and evaluated Foundayo across multiple dose levels over 72 weeks. Participants on the highest Foundayo dose who remained on treatment lost an average of approximately 12.4% of their starting body weight, compared with 0.9% for participants on placebo. This is a statistically significant and clinically meaningful difference that demonstrates unambiguously that Foundayo works. Participants who lost weight also showed meaningful improvements in cardiometabolic markers including blood pressure, waist circumference, lipid profiles, and fasting glucose. These findings are consistent with the broader metabolic benefits observed with other GLP-1 receptor agonists.
ATTAIN-2 studied a different population: adults with both obesity and type 2 diabetes, a group in which weight loss is typically more challenging due to the underlying metabolic and hormonal dysregulation associated with diabetes. In this trial, participants on the highest Foundayo dose lost an average of approximately 10.5% of body weight alongside reductions in HbA1c of up to 1.8 percentage points from baseline. These are meaningful outcomes in a population for whom even modest weight loss produces significant clinical benefit. The dual action on both body weight and glycaemic control is particularly relevant for patients who are managing both conditions simultaneously. The ATTAIN trial programme as a whole provides a robust evidence base for Foundayo’s effectiveness across two of the most clinically important patient populations in weight management.
Foundayo vs Other GLP-1 Treatments
Positioning Foundayo’s effectiveness accurately requires an important caveat. The weight loss figures for different GLP-1 medications come from separate clinical trials with different populations, different designs, and different follow-up periods. They should therefore be compared directionally rather than as precise head-to-head data.. With that context clearly in place, the available evidence suggests that Foundayo produces average weight loss at the lower end of the GLP-1 spectrum currently available in the UK. Mounjaro, with average weight loss of approximately 20 to 22% of body weight in the SURMOUNT-1 trial, remains the most effective treatment in the class. Injectable Wegovy sits at approximately 15% in the STEP-1 trial. The Wegovy pill, which received MHRA approval in June 2026 with commercial availability developing progressively, sits at approximately 13 to 15%. Foundayo, at approximately 11 to 12%, is the most recent addition and produces the lowest average weight loss figures across the class — though as noted, these comparisons involve different trial populations.
What the comparison does not capture is the practical effectiveness advantage that Foundayo’s administration flexibility may deliver in real-world use. Clinical trial efficacy figures are generated in controlled conditions with high adherence support and regular monitoring. In real-world clinical practice, adherence to a treatment that fits naturally into a patient’s daily life without specific timing requirements, food restrictions, or injection anxiety may be meaningfully higher than adherence to a treatment with greater theoretical efficacy but more demanding administration requirements. A treatment that produces 12% average weight loss but is taken consistently may ultimately outperform a treatment capable of 20% in a patient who struggles to maintain their injection schedule or finds the Wegovy pill’s administration requirements difficult to sustain.
Foundayo vs Wegovy vs Mounjaro
Use the comparison below to see how Foundayo sits alongside the other GLP-1 weight loss treatments currently licensed or recently approved for use in the UK. All weight loss figures are from the highest approved or studied doses in the relevant clinical trials and represent averages across trial populations rather than predictive individual outcomes.
| Treatment | Average weight loss | Trial | Format | Administration |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | Around 20 to 22% | SURMOUNT-1 | Weekly injection | No food or water restrictions |
| Wegovy injection (semaglutide) | Around 15% | STEP-1 | Weekly injection | No food or water restrictions |
| Wegovy pill (oral semaglutide) | Around 13 to 15% | Oral semaglutide trials | Daily pill | Empty stomach; 30 min before food; small sip of water only |
| Foundayo (orforglipron) | Around 11 to 12% | ATTAIN-1 | Daily pill | No food or water restrictions; any time of day |
Understanding which weight loss treatment is genuinely the most effective option for your individual circumstances requires a thorough, personalised clinical assessment. The team at J E Williamson Pharmacy in Bishops Stortford brings that expertise to every patient consultation. Call our team today and find out which of the MHRA-licensed weight loss treatments now available is the most clinically appropriate and practically sustainable choice for you.
How Adherence Shapes Foundayo Outcomes
One of the most clinically significant but frequently overlooked dimensions of any weight loss treatment’s effectiveness is real-world adherence. Clinical trial efficacy is measured under conditions designed to maximise adherence: participants are closely monitored, provided with dietary counselling and support, and are motivated by trial participation in ways that do not necessarily translate to everyday life. When treatments reach real-world clinical use, adherence typically falls below trial levels, and treatments that are more complex to administer consistently tend to see greater real-world adherence challenges than simpler alternatives. The Wegovy pill requires a specific morning administration routine that must precede any food, drink, or other oral medication. Many patients manage this successfully, but some find it genuinely difficult to maintain consistently over months or years.. Foundayo’s administration flexibility removes this requirement entirely, potentially supporting more consistent real-world adherence for patients who struggle with structured morning routines.
The ATTAIN-MAINTAIN trial addresses a related and clinically important question: can patients who have achieved significant weight loss on injectable GLP-1 treatments transition to Foundayo as an oral maintenance option? Early results suggest this may be a viable strategy for some patients. It opens an interesting clinical pathway for those currently on Mounjaro or injectable Wegovy who want to explore whether a transition to oral maintenance treatment suits their longer-term plan. This is a clinical discussion worth having with a prescribing clinician, as individual suitability will depend on a range of factors including the extent of weight loss achieved, current dose level, and overall treatment response.
Who Benefits Most from the Foundayo Pill?
The clinical case for Foundayo is strongest when viewed through the lens of the patient groups most likely to benefit from it specifically. Measuring it solely against the weight loss figures of injectable alternatives overlooks the fact that those alternatives may not be appropriate or accessible for every patient. Patients who are needle-averse and have been avoiding GLP-1 treatment entirely because of unwillingness to self-inject represent one of the most significant groups for whom Foundayo’s arrival is genuinely meaningful. The meaningful choice for needle-averse patients is not between Foundayo and a more potent injectable but between Foundayo and forgoing GLP-1 treatment entirely, which places its 11 to 12% average weight loss in a considerably more compelling clinical light. Patients who have tried the Wegovy pill but found its morning administration requirements difficult to maintain consistently represent a second group for whom Foundayo may deliver better real-world results despite its lower clinical trial average, because consistent administration of a less potent treatment consistently outperforms inconsistent administration of a more potent one.
Patients with type 2 diabetes alongside obesity represent a third important group, given that Foundayo is MHRA-authorised for both conditions and the ATTAIN-2 trial demonstrated meaningful dual benefits on both body weight and glycaemic control. Clinicians managing patients with both obesity and type 2 diabetes may find particular value in Foundayo’s ability to address both conditions through a single flexible oral agent. This is especially relevant for patients whose existing medication burden makes the addition of a weekly injection impractical or unwelcome. Patients whose primary weight loss goal is achieving and maintaining a specific clinical threshold rather than maximum possible weight loss may also find that Foundayo’s efficacy profile is well-matched to their needs.
Foundayo Side Effects
A treatment’s real-world effectiveness is always influenced by its tolerability, because side effects that lead to dose reduction, treatment interruption, or discontinuation directly reduce the medication’s opportunity to deliver its full clinical potential. Foundayo’s most commonly reported side effects are gastrointestinal in nature, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, which is consistent with the broader GLP-1 medication class. These effects are most pronounced during the dose escalation phase and typically improve as the body adjusts at each dose level. The ACHIEVE-3 trial found that Foundayo produced somewhat higher rates of gastrointestinal side effects and treatment discontinuation than oral semaglutide. This is a relevant consideration for patients with a known history of poor gastrointestinal tolerability on GLP-1 medications. Headache and fatigue are also commonly reported, particularly in the early weeks of treatment.
The Foundayo titration schedule, which begins at 0.8mg daily and progresses over approximately five months to the 17.2mg maintenance dose with a minimum of thirty days at each level, is specifically designed to minimise side effect severity by allowing gradual adaptation at each dose. Prescribers can extend the time spent at any dose level if tolerability requires it, and not all patients need to reach the highest maintenance dose. Managing side effects proactively, with clinical support and dietary adjustments during the most vulnerable early dose escalation phases, significantly improves both tolerability and long-term treatment effectiveness. UK-specific prescribing and titration guidance is set out in the MHRA-approved Summary of Product Characteristics and should always be followed by prescribing clinicians.
How to Maximise the Effectiveness of Foundayo
Like all GLP-1 weight loss treatments, Foundayo is most effective when used within a comprehensive weight management approach that combines the pharmacological appetite suppression it provides with active dietary and lifestyle changes. Clinical trial participants in the ATTAIN programme received dietary counselling and support alongside their medication, and the average weight loss figures from these trials reflect this combination rather than the medication alone. Patients who make meaningful dietary changes alongside Foundayo consistently achieve better outcomes than those who rely on appetite suppression alone. Prioritising protein-rich, fibre-rich, minimally processed foods and reducing calorie-containing beverages and ultra-processed snack foods are the most impactful dietary adjustments. Increasing physical activity, improving sleep quality, and managing stress all contribute to the overall calorie balance and metabolic environment in which Foundayo operates. Each represents an additional lever that can meaningfully improve outcomes beyond the medication’s direct pharmacological effect.
Regular clinical monitoring throughout treatment is also an important component of maximising Foundayo’s real-world effectiveness. A prescribing clinician or pharmacist who reviews progress, identifies limiting factors, and helps patients navigate plateaus is providing a service that directly amplifies the medication’s clinical potential.. Patients who access Foundayo through a properly regulated, well-monitored clinical service consistently achieve better outcomes than those who use it with minimal oversight, and the clinical team at J E Williamson Pharmacy in Bishops Stortford provides exactly this standard of support as a core part of every weight management consultation.
Maximising the effectiveness of Foundayo requires the right clinical support from the very beginning of treatment. Every patient at J E Williamson Pharmacy in Bishops Stortford benefits from personalised dietary guidance, ongoing progress monitoring, and expert clinical support throughout their weight loss journey. Contact us to book a consultation and place your weight loss treatment in the hands of a clinical team that is genuinely invested in helping you achieve the very best results the treatment is capable of delivering.
Frequently Asked Questions
From expected weight loss to how Foundayo compares to existing treatments, here are the effectiveness questions the clinical team at J E Williamson Pharmacy in Bishops Stortford fields most consistently from patients who are considering or have recently started Foundayo.
How much weight can I expect to lose on Foundayo?
The ATTAIN-1 trial reported average weight loss of approximately 12.4% of body weight over 72 weeks in adults with obesity without type 2 diabetes at the highest Foundayo dose, though individual results vary considerably depending on starting weight, dietary habits, lifestyle factors, and dose level reached. The most meaningful weight loss on Foundayo typically occurs from around week 16 onwards, once patients are approaching or established at the maintenance dose.
How long does Foundayo take to work?
Most patients begin to experience some degree of appetite reduction within the first few weeks of starting Foundayo, though significant and consistent weight loss on the scales typically becomes more apparent from around weeks eight to twelve as the dose increases towards therapeutic levels. The full weight loss potential of Foundayo is not realised until patients are established at or near the maintenance dose of 17.2mg, which is reached after approximately five months of dose escalation.
Is Foundayo more effective than the Wegovy pill?
In the ACHIEVE-3 head-to-head trial in adults with type 2 diabetes, Foundayo produced greater HbA1c reductions and slightly higher weight loss than oral semaglutide, though with somewhat higher rates of gastrointestinal side effects and discontinuation. This trial studied a specific population with type 2 diabetes, and findings should not be automatically generalised to all patient groups or directly compared to injectable Wegovy efficacy figures.
Will Foundayo work for me if Wegovy or Mounjaro did not?
Yes, Foundayo received MHRA authorisation on 10 August 2026 for both weight management and type 2 diabetes, and the ATTAIN-2 trial demonstrated meaningful reductions in both body weight and HbA1c in adults with obesity and type 2 diabetes. The dual action on both body weight and glycaemic control makes Foundayo a particularly relevant option for patients who are managing both conditions simultaneously and are seeking a single flexible oral treatment.
Does Foundayo work for type 2 diabetes as well as weight loss?
Switching from an injectable GLP-1 treatment to Foundayo may be appropriate for some patients, and the ATTAIN-MAINTAIN trial explored this specifically as a long-term maintenance strategy following initial weight loss on injectable GLP-1s. Any decision to switch should be made in full consultation with a prescribing clinician who can assess your individual circumstances, treatment history, and suitability for Foundayo before any change is made.
What happens to my weight if I stop taking Foundayo?
As with all GLP-1 weight loss medications, stopping Foundayo is associated with weight regain over time, as the pharmacological appetite suppression that facilitated the calorie deficit is removed. The ATTAIN-MAINTAIN trial specifically examined strategies for maintaining weight loss after GLP-1 treatment, and the clinical evidence consistently supports either continuation of treatment or a structured transition plan developed with a prescribing clinician to protect the results achieved during active treatment.
Foundayo Availability in the UK
The Foundayo pill is a genuinely effective, MHRA-authorised weight loss treatment whose clinical trial results demonstrate meaningful weight loss outcomes and significant cardiometabolic benefits for eligible patients. Its efficacy sits at the lower end of the GLP-1 spectrum currently available in the UK. For patients for whom oral, restriction-free administration is the decisive factor in sustaining treatment consistently, it represents a genuinely important and clinically valuable option. The expert clinical team at J E Williamson Pharmacy in Bishops Stortford is committed to helping every patient make a genuinely informed decision about whether Foundayo is the right treatment for their circumstances or whether Mounjaro, Wegovy, or another licensed approach would deliver better outcomes for their individual health profile and weight loss ambitions. Book now and start your weight loss journey with the clinical expertise, personalised guidance, and ongoing support that makes the difference between a treatment that is merely taken and one that truly delivers.
